Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Can needle-free administration of vaccines become the norm in global immunization?

Nature Medicine volume 9, pages 99–103 (2003)Cite this article

If vaccines could be administered without needles and syringes ('sharps'), immunization practice would become safer, more accepted and more suitable for mass use. The author explores the status of technologies that could achieve this aim and the barriers that must be overcome for their implementation.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Aylward, B., Lloyd, J., Zaffran, M., McNair-Scott, R. & Evans, P. Reducing the risk of unsafe injections in immunization programmes: financial and operational implications of various injection technologies. Bull. World Health Org. 73, 531–540 (1995).

    CAS  PubMed  Google Scholar 

  2. Simonsen, L., Kane, A., Lloyd, J., Zaffran, M. & Kane, M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull. World Health Org. 77, 789–800 (1999).

    CAS  PubMed  Google Scholar 

  3. Levine, M.M. & Dougan, G. Optimism over vaccines administered via mucosal surfaces. Lancet 351, 1375–1376 (1998).

    Article  CAS  Google Scholar 

  4. Neutra, M.R., Frey, A. & Kraehenbuhl, J.P. Epithelial M cells: gateways for mucosal infection and immunization. Cell 86, 345–348 (1996).

    Article  CAS  Google Scholar 

  5. Levine, M.M. et al. Duration of efficacy of ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 17 (Suppl 2), S22–S27 (1999).

    Article  Google Scholar 

  6. Levine, M.M. & Kaper, J.B. Live oral cholera vaccine: from principle to product. Bull. Inst. Pasteur 93, 243–253 (1995).

    Article  Google Scholar 

  7. Sanchez, J.L. et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 344, 1273–1276 (1994).

    Article  CAS  Google Scholar 

  8. Trach, D.D. et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349, 231–235 (1997).

    Article  CAS  Google Scholar 

  9. Murphy, T.V. et al. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 344, 564–572 (2001).

    Article  CAS  Google Scholar 

  10. John, T.J. & Jayabal, P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am. J. Epidemiol. 96, 263–269 (1972).

    Article  CAS  Google Scholar 

  11. Gotuzzo, E. et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun. 61, 3994–3997 (1993).

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Hanlon, P. et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1, 1342–1345 (1987).

    Article  CAS  Google Scholar 

  13. Lagos, R. et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 180, 1709–1712 (1999).

    Article  CAS  Google Scholar 

  14. Cooper, P.J. et al. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 182, 1199–1206 (2000).

    Article  CAS  Google Scholar 

  15. Pasetti, M.F., Anderson, R.J., Noriega, F.R., Levine, M.M. & Sztein, M.B. Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin. Immunol. 92, 76–89 (1999).

    Article  CAS  Google Scholar 

  16. Tacket, C.O. et al. Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin. Immunol. 97, 146–153 (2000).

    Article  CAS  Google Scholar 

  17. Tacket, C.O. et al. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nature Med. 4, 607–609 (1998).

    Article  CAS  Google Scholar 

  18. Tacket, C.O. et al. Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres. Vaccine 12, 1270–1274 (1994).

    Article  CAS  Google Scholar 

  19. Belshe, R.B. et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N. Engl. J. Med. 338, 1405–1412 (1998).

    Article  CAS  Google Scholar 

  20. King, J.C., Jr. et al. Safety and immunogenicity of low and high doses of trivalent live cold- adapted influenza vaccine administered intranasally as drops or spray to healthy children. J. Infect. Dis. 177, 1394–1397 (1998).

    Article  Google Scholar 

  21. Levine, M., Kaper, J., Black, R.E. & Clements, M. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47, 510–550 (1983).

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Gluck, R. et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181, 1129–1132 (2000).

    Article  CAS  Google Scholar 

  23. Douce, G. et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 92, 1644–1648 (1995).

    Article  CAS  Google Scholar 

  24. Yamamoto, S. et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185, 1203–1210 (1997).

    Article  CAS  Google Scholar 

  25. Van Ginkel, F.W., Jackson, R.J., Yuki, Y. & McGhee, J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165, 4778–4782 (2000).

    Article  CAS  Google Scholar 

  26. Agren, L.C., Ekman, L., Lowenadler, B., Nedrud, J.G. & Lycke, N.Y. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162, 2432–2440 (1999).

    CAS  PubMed  Google Scholar 

  27. Dilraj, A. et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet 355, 798–803 (2000).

    Article  CAS  Google Scholar 

  28. Fernandez-de Castro, J., Kumate-Rodriguez, J., Sepulveda, J., Ramirez-Isunza, J.M. & Valdespino-Gomez, J.L. La vacunacion antisarampionosa en Mexico por el metodo de aerosol. Salud Publica Mex. 39, 53–60 (1997).

    Article  CAS  Google Scholar 

  29. Hingson, R.A., Davis, H.S. & Rosen, M. The historical development of jet injection and envisioned uses in mass immunization and mass therapy based upon two decades experience. Milit. Med. 128, 516–524 (1963).

    Article  Google Scholar 

  30. Canter, J. et al. An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. Arch. Intern. Med 150, 1923–1927 (1990).

    Article  CAS  Google Scholar 

  31. Cohen Reis, E., Jacobsen, R.M., Tarbell, S. & Weniger, B.G. Taking the sting out of shots: control of vaccination-associated pain and adverse reactions. Pediatr. Ann. 27, 375–386 (1998).

    Article  Google Scholar 

  32. Jackson, L.A. et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 19, 4703–4709 (2001).

    Article  CAS  Google Scholar 

  33. Jodar, L. et al. Ensuring vaccine safety in immunization programmes—a WHO perspective. Vaccine 19, 1594–1605 (2001).

    Article  CAS  Google Scholar 

  34. Parent du Chatelet, I. et al. Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (Imule): comparison with standard syringe injection. Imule Investigators Group. Vaccine 15, 449–458 (1997).

    Article  CAS  Google Scholar 

  35. Roy, M.J. et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19, 764–778 (2000).

    Article  CAS  Google Scholar 

  36. Glenn, G.M., Rao, M., Matyas, G.R. & Alving, C.R. Skin immunization made possible by cholera toxin. Nature 391, 851–851 (1998).

    Article  CAS  Google Scholar 

  37. Guerena-Burgueno, F. et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 70, 1874–1880 (2002).

    Article  CAS  Google Scholar 

  38. Mikszta, J.A. et al. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nature Med. 8, 415–419 (2002).

    Article  CAS  Google Scholar 

  39. Levine, M.M., Campbell, J.D. & Kotloff, K.L. Overview of vaccines and immunisation. Br. Med. Bull. 62, 1–13 (2002).

    Article  Google Scholar 

  40. Summary of the joint statement on thimerosal in vaccines. American Academy of Family Physicians, American Academy of Pediatrics, Advisory Committee on Immunization Practices, Public Health Service. MMWR Morb. Mortal. Wkly. Rep. 49, 622, 631 (2000).

Download references

Author information

Authors and Affiliations

  1. Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland

    Myron M. Levine

  2. Task Force on Research and Development, Global Alliance for Vaccines and Immunization,

    Myron M. Levine

Authors
  1. Myron M. Levine
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levine, M. Can needle-free administration of vaccines become the norm in global immunization?. Nat Med 9, 99–103 (2003). https://doi.org/10.1038/nm0103-99

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nm0103-99

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing